CR20210495A - Compuestos macrocíclicos como agonistas de sting - Google Patents
Compuestos macrocíclicos como agonistas de stingInfo
- Publication number
- CR20210495A CR20210495A CR20210495A CR20210495A CR20210495A CR 20210495 A CR20210495 A CR 20210495A CR 20210495 A CR20210495 A CR 20210495A CR 20210495 A CR20210495 A CR 20210495A CR 20210495 A CR20210495 A CR 20210495A
- Authority
- CR
- Costa Rica
- Prior art keywords
- macrocyclic compounds
- sting agonists
- compounds
- disclosed
- macrocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921012258 | 2019-03-28 | ||
IN201921046194 | 2019-11-13 | ||
PCT/IB2020/052654 WO2020194160A1 (en) | 2019-03-28 | 2020-03-21 | Macrocyclic compounds as sting agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210495A true CR20210495A (es) | 2021-10-18 |
Family
ID=70293003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210495A CR20210495A (es) | 2019-03-28 | 2020-03-21 | Compuestos macrocíclicos como agonistas de sting |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220144852A1 (es) |
EP (1) | EP3946610A1 (es) |
JP (1) | JP2022527306A (es) |
KR (1) | KR20210146370A (es) |
CN (1) | CN113631228B (es) |
AU (1) | AU2020245263A1 (es) |
BR (1) | BR112021018947A2 (es) |
CA (1) | CA3132508A1 (es) |
CL (1) | CL2021002480A1 (es) |
CO (1) | CO2021012559A2 (es) |
CR (1) | CR20210495A (es) |
EC (1) | ECSP21071644A (es) |
IL (1) | IL286526A (es) |
MA (1) | MA55517A (es) |
MX (1) | MX2021011686A (es) |
PE (1) | PE20220169A1 (es) |
SG (1) | SG11202109191SA (es) |
WO (1) | WO2020194160A1 (es) |
ZA (1) | ZA202106629B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20220029A (es) * | 2019-07-22 | 2022-03-14 | Lupin Ltd | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos |
US11155567B2 (en) | 2019-08-02 | 2021-10-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
JPWO2021206158A1 (es) | 2020-04-10 | 2021-10-14 | ||
EP4277904A1 (en) * | 2021-01-15 | 2023-11-22 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
JP6835727B2 (ja) * | 2015-02-05 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Irak1/4阻害剤としての大環状化合物及びその使用 |
WO2017011920A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
RU2018137389A (ru) | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
MX2018012333A (es) * | 2016-04-07 | 2019-03-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas. |
WO2018234805A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | SMALL MOLECULAR MODULATORS OF HUMAN STING |
EP3642198B1 (en) | 2017-06-22 | 2022-03-16 | Curadev Pharma Limited | Small molecule modulators of human sting |
US20200172483A1 (en) | 2017-06-22 | 2020-06-04 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
EP3658138B1 (en) | 2017-07-27 | 2023-04-19 | Stingray Therapeutics, Inc. | Substituted-3h-imidazo(4,5-c)pyridine and 1h-pyrrolo(2,3-c)pyridine series of novel ectonucleotide pyrophsphatase/phosphodiestrase-1 (enpp1) and stimulator for interferon genes (sting) modulator as cancer immunotherapeutics |
AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
CA3071537A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and benzo[b]thiophene sting agonists for cancer treatment |
-
2020
- 2020-03-21 US US17/598,524 patent/US20220144852A1/en active Pending
- 2020-03-21 CR CR20210495A patent/CR20210495A/es unknown
- 2020-03-21 WO PCT/IB2020/052654 patent/WO2020194160A1/en active Application Filing
- 2020-03-21 MA MA055517A patent/MA55517A/fr unknown
- 2020-03-21 CN CN202080025785.1A patent/CN113631228B/zh active Active
- 2020-03-21 MX MX2021011686A patent/MX2021011686A/es unknown
- 2020-03-21 AU AU2020245263A patent/AU2020245263A1/en active Pending
- 2020-03-21 JP JP2021557830A patent/JP2022527306A/ja active Pending
- 2020-03-21 SG SG11202109191SA patent/SG11202109191SA/en unknown
- 2020-03-21 BR BR112021018947A patent/BR112021018947A2/pt unknown
- 2020-03-21 PE PE2021001577A patent/PE20220169A1/es unknown
- 2020-03-21 EP EP20719719.5A patent/EP3946610A1/en active Pending
- 2020-03-21 KR KR1020217035108A patent/KR20210146370A/ko unknown
- 2020-03-21 CA CA3132508A patent/CA3132508A1/en active Pending
-
2021
- 2021-09-08 ZA ZA2021/06629A patent/ZA202106629B/en unknown
- 2021-09-19 IL IL286526A patent/IL286526A/en unknown
- 2021-09-24 EC ECSENADI202171644A patent/ECSP21071644A/es unknown
- 2021-09-24 CL CL2021002480A patent/CL2021002480A1/es unknown
- 2021-09-24 CO CONC2021/0012559A patent/CO2021012559A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022527306A (ja) | 2022-06-01 |
PE20220169A1 (es) | 2022-01-28 |
KR20210146370A (ko) | 2021-12-03 |
CL2021002480A1 (es) | 2022-04-29 |
CN113631228B (zh) | 2023-10-13 |
US20220144852A1 (en) | 2022-05-12 |
EP3946610A1 (en) | 2022-02-09 |
SG11202109191SA (en) | 2021-09-29 |
CN113631228A (zh) | 2021-11-09 |
BR112021018947A2 (pt) | 2022-02-08 |
CO2021012559A2 (es) | 2021-09-30 |
WO2020194160A1 (en) | 2020-10-01 |
AU2020245263A1 (en) | 2021-10-07 |
IL286526A (en) | 2021-10-31 |
CA3132508A1 (en) | 2020-10-01 |
MA55517A (fr) | 2022-02-09 |
ZA202106629B (en) | 2022-07-27 |
ECSP21071644A (es) | 2021-12-30 |
MX2021011686A (es) | 2021-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021011686A (es) | Compuestos macrociclicos como agonistas de sting. | |
MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
MX2020012520A (es) | Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia. | |
MX2022000939A (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos. | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MX2021006265A (es) | Derivados de panteteina y usos de los mismos. | |
MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
MY194116A (en) | Pharmaceutical compounds | |
WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
MX2021007247A (es) | Derivados de rapamicina. | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
MX2019011182A (es) | Combinacion de derivados de isoindolinona con sgi-110. | |
ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
TR201714882A2 (tr) | Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari | |
NZ775905A (en) | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators | |
MX2021014458A (es) | Compuestos triciclicos. |